Company research
Rallybio Corp
CIK 1739410Updated Nov 13, 2026
SecurityRLYB · NASDAQ · equity
Name history
Rallybio Holdings, LLC · through Jun 7, 2021
RLYB price & chart
Loading TradingView…
NASDAQ:RLYB on TradingView ↗About the company
Rallybio (Nasdaq: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of complement dysregulation and hematology.
In the news
Recent filings
425 filing
Other Events
Items 8.01
425 filing
Other Events
Items 8.01, 9.01
425 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 67,661,000Source | 79,007,000Source | 98,063,000Source | 51,003,000Source | 92,431,000Source | 54,472,000Source | 57,983,000Source | 99,359,000Source | 62,261,000Source | 68,108,000Source | 115,620,000Source | 180,435,000Source |
| Property, Plant and Equipment, NetUSD | 26,000Source | 145,000Source | 0Source | 61,000Source | 177,000Source | 20,000Source | 87,000Source | 211,000Source | 23,000Source | 115,000Source | 246,000Source | 385,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 32,122,000Source | 25,320,000Source | 92,849,000Source | 9,445,000Source | 16,671,000Source | 41,299,000Source | 14,779,000Source | 19,301,000Source | 31,374,000Source | 13,903,000Source | 24,494,000Source | 56,958,000Source |
| Assets, CurrentUSD | 66,627,000Source | 78,230,000Source | 97,253,000Source | 50,265,000Source | 91,436,000Source | 53,490,000Source | 57,381,000Source | 98,545,000Source | 61,253,000Source | 67,841,000Source | 114,789,000Source | 179,496,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,308,000Source | 3,091,000Source | 4,404,000Source | 4,516,000Source | 2,822,000Source | 6,695,000Source | 2,886,000Source | 4,370,000Source | 6,517,000Source | 2,330,000Source | 4,860,000Source | 10,502,000Source |
| Operating Lease, Right-of-Use AssetUSD | 198,000Source | 201,000Source | 0Source | 51,000Source | 250,000Source | 152,000Source | 102,000Source | 299,000Source | 175,000Source | 152,000Source | 346,000Source | 524,000Source |
| Other Assets, NoncurrentUSD | 810,000Source | — | 810,000Source | — | — | 810,000Source | — | — | 810,000Source | — | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 4,627,000Source | 8,189,000Source | 3,567,000Source | 5,039,000Source | 12,414,000Source | 4,195,000Source | 3,910,000Source | 10,202,000Source | 4,305,000Source | 6,454,000Source | 9,436,000Source | 11,118,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 4,000Source | 4,000Source | 4,000Source | 4,000Source | 4,000Source | 4,000Source | 4,000Source | 4,000Source | 4,000Source | 4,000Source | 4,000Source | 4,000Source |
| Additional Paid in CapitalUSD | 359,152,000Source | 352,621,000Source | 361,103,000Source | 358,105,000Source | 350,594,000Source | 360,548,000Source | 356,481,000Source | 343,498,000Source | 359,932,000Source | 354,602,000Source | 341,410,000Source | 330,208,000Source |
| Retained Earnings (Accumulated Deficit)USD | -296,146,000Source | -281,976,000Source | -266,611,000Source | -312,162,000Source | -270,510,000Source | -310,276,000Source | -302,459,000Source | -254,274,000Source | -301,998,000Source | -293,020,000Source | -235,245,000Source | -160,681,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 24,000Source | 169,000Source | 0Source | 17,000Source | -71,000Source | 1,000Source | 47,000Source | -71,000Source | 18,000Source | 68,000Source | 15,000Source | -214,000Source |
| Stockholders' Equity Attributable to ParentUSD | 63,034,000Source | 70,818,000Source | 94,496,000Source | 45,964,000Source | 80,017,000Source | 50,277,000Source | 54,073,000Source | 89,157,000Source | 57,956,000Source | 61,654,000Source | 106,184,000Source | 169,317,000Source |
| Liabilities and EquityUSD | 67,661,000Source | 79,007,000Source | 98,063,000Source | 51,003,000Source | 92,431,000Source | 54,472,000Source | 57,983,000Source | 99,359,000Source | 62,261,000Source | 68,108,000Source | 115,620,000Source | 180,435,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 4,519,000Source | 8,189,000Source | 3,567,000Source | 5,039,000Source | 12,161,000Source | 4,140,000Source | 3,910,000Source | 10,086,000Source | 4,223,000Source | 6,242,000Source | 9,263,000Source | 10,744,000Source |
| Operating Lease, Liability, CurrentUSD | 90,000Source | 230,000Source | 0Source | 58,000Source | 226,000Source | 99,000Source | 116,000Source | 223,000Source | 94,000Source | 154,000Source | 219,000Source | 181,000Source |
| Accounts Payable, CurrentUSD | 269,000Source | 583,000Source | 833,000Source | 119,000Source | 1,218,000Source | 940,000Source | 400,000Source | 470,000Source | 126,000Source | 278,000Source | 976,000Source | 1,114,000Source |
| Operating Lease, Liability, NoncurrentUSD | 108,000Source | 0Source | 0Source | — | 58,000Source | 55,000Source | — | 116,000Source | 82,000Source | 0Source | 173,000Source | 374,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 3,736,000Source | 6,279,000Source | 1,465,000Source | 4,226,000Source | 9,515,000Source | 3,101,000Source | 2,546,000Source | 9,393,000Source | 3,791,000Source | 4,962,000Source | 8,068,000Source | 9,449,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 59,300,000Source | 75,100,000Source | 92,800,000Source | 45,700,000Source | 88,600,000Source | 46,800,000Source | 54,500,000Source | 94,200,000Source | 54,700,000Source | 65,500,000Source | 109,900,000Source | 169,000,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 613,000Source | 1,879,000Source | 5,314,000Source | 7,993,000Source | 10,920,000Source | 9,499,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 814,000Source | 122,000Source | -152,000Source | -698,000Source | -99,000Source | 487,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -7,978,000Source | -10,205,000Source | -29,813,000Source | -49,282,000Source | -60,265,000Source | -57,284,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 17,900,000Source | 11,081,000Source | 47,268,000Source | 33,492,000Source | 27,658,000Source | -112,170,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 0Source | 12,000Source | 54,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 3,000Source | 0Source | 16,000Source | 5,199,000Source | 143,000Source | 51,078,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 9,925,000Source | 876,000Source | 17,471,000Source | -10,591,000Source | -32,464,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 32,122,000Source | 25,320,000Source | 92,849,000Source | 9,445,000Source | 41,299,000Source | 14,779,000Source | 31,374,000Source | 13,903,000Source | 24,494,000Source | 56,958,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,047,000Source | 2,027,000Source | 424,000Source | 1,614,000Source | 613,000Source | 1,879,000Source | 5,314,000Source | 7,993,000Source | 10,920,000Source | 9,499,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 59,300,000Source | 75,100,000Source | 92,800,000Source | 45,700,000Source | 46,800,000Source | 54,500,000Source | 54,700,000Source | 65,500,000Source | 109,900,000Source | 169,000,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 100,000Source | 100,000Source | 100,000Source | 200,000Source |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | — | — | — | — | — | — | — | — | 22,350,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 2,994,000Source | 4,125,000Source | 4,895,000Source | 4,195,000Source | 6,074,000Source | 4,157,000Source | 14,325,000Source | 19,625,000Source | 25,388,000Source | 27,195,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | 0Source | -637,000Source | 0Source | -287,000Source | 0Source | -587,000Source | -874,000Source | -2,239,000Source | -2,041,000Source | -1,075,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 1,324,000Source | 0Source | — | — | 0Source | 0Source | 0Source | 0Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | 7,000Source | 240,000Source | -1,000Source | -30,000Source | -17,000Source | -21,000Source | -50,000Source | 53,000Source | 229,000Source | -214,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 16,016,000Source | -11,466,000Source | 43,665,000Source | -9,703,000Source | -8,278,000Source | -9,439,000Source | -8,978,000Source | -57,775,000Source | -74,564,000Source | -66,654,000Source |
| Nonoperating Income (Expense)USD | — | — | 22,941,000Source | 1,237,000Source | 50,642,000Source | 641,000Source | 455,000Source | 818,000Source | 24,960,000Source | 4,960,000Source | 6,409,000Source | 2,305,000Source |
| Operating ExpensesUSD | — | — | 7,137,000Source | 12,365,000Source | 5,653,000Source | 10,269,000Source | 8,945,000Source | 9,882,000Source | 33,922,000Source | 61,132,000Source | 78,932,000Source | 67,884,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 22,479,000Source | 251,000Source | 424,000Source | 118,000Source | 254,000Source | 174,000Source | 22,771,000Source | 744,000Source | 262,000Source | 342,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 3,000Source | 0Source | 0Source | 5,405,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 21,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 212,000Source | 299,000Source | 0Source | 212,000Source | 212,000Source | 212,000Source | 858,000Source | 600,000Source | — | — |
| Operating Income (Loss)USD | — | — | -6,925,000Source | -12,066,000Source | -5,653,000Source | -10,057,000Source | -8,733,000Source | -9,670,000Source | -33,064,000Source | -60,496,000Source | -78,932,000Source | -67,884,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 22,479,000Source | 251,000Source | 424,000Source | 118,000Source | 254,000Source | 174,000Source | 22,771,000Source | 744,000Source | 262,000Source | 342,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -8,978,000Source | — | — | -65,579,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 1,324,000Source | 0Source | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 16,016,000Source | -11,466,000Source | 43,665,000Source | -9,703,000Source | -8,278,000Source | -9,439,000Source | -8,978,000Source | -57,775,000Source | -74,564,000Source | -66,654,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.36Source | -0.26Source | 7.66Source | -1.73Source | -1.46Source | -1.69Source | -1.59Source | -1.33Source | -1.84Source | -2.09Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.36Source | -0.26Source | 7.53Source | -0.22Source | -1.46Source | -1.69Source | -1.59Source | -1.33Source | -1.84Source | -2.09Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 45,058,591Source | 44,593,221Source | 5,699,111Source | 5,605,116Source | 5,688,584Source | 5,597,528Source | 5,629,370Source | 43,544,824Source | 40,447,388Source | 31,821,311Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 45,058,591Source | 44,593,221Source | 5,797,913Source | 44,841,140Source | 5,688,584Source | 5,597,528Source | 5,629,370Source | 43,544,824Source | 40,447,388Source | 31,821,311Source |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 3,000Source | 28,000Source | 92,000Source | 131,000Source | 150,000Source | 167,000Source |
| General and Administrative ExpenseUSD | — | — | 2,994,000Source | 4,125,000Source | 4,895,000Source | 4,195,000Source | 6,074,000Source | 4,157,000Source | 14,325,000Source | 19,625,000Source | 25,388,000Source | 27,195,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -8,978,000Source | — | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | 0Source | -637,000Source | 0Source | -287,000Source | 0Source | -587,000Source | -874,000Source | -2,239,000Source | -2,041,000Source | -1,075,000Source |
| Interest and Other IncomeUSD | — | — | 462,000Source | 986,000Source | 218,000Source | 523,000Source | 201,000Source | 644,000Source | 2,189,000Source | 4,216,000Source | 6,147,000Source | 1,963,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Nonoperating Income (Expense)USD | — | — | 22,941,000Source | 1,237,000Source | 50,642,000Source | 641,000Source | 455,000Source | 818,000Source | 24,960,000Source | 4,960,000Source | 6,409,000Source | 2,305,000Source |
| Operating ExpensesUSD | — | — | 7,137,000Source | 12,365,000Source | 5,653,000Source | 10,269,000Source | 8,945,000Source | 9,882,000Source | 33,922,000Source | 61,132,000Source | 78,932,000Source | 67,884,000Source |
| Research and Development ExpenseUSD | — | — | 4,143,000Source | 8,240,000Source | 758,000Source | 6,074,000Source | 2,871,000Source | 5,725,000Source | 19,597,000Source | 41,507,000Source | 53,544,000Source | 40,689,000Source |
| Restructuring and Related Cost, Incurred Cost | — | — | — | — | — | —Source | — | — | — | — | — | — |
Offerings
Registration 333-297483
Registration 333-294361
Filing attachments
d162317dex991.htm · 425 · 2026-11-10
Exhibit 99.1 Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo EAST BERLIN, Conn., November 10, 2026 - Rallybio Corporation (Nasdaq: RLYB) today announced that it will effect a one-for-two reverse stock split of its issued and outstanding common stock in connection with the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated as of May 31, 2026, among Rallybio, Avenzo Therapeutics, Inc. (“Avenzo”) and Fa…
Read attachment ↗d162317dex991.htm · 8-K · 2026-11-10
Exhibit 99.1 Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo EAST BERLIN, Conn., November 10, 2026 - Rallybio Corporation (Nasdaq: RLYB) today announced that it will effect a one-for-two reverse stock split of its issued and outstanding common stock in connection with the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated as of May 31, 2026, among Rallybio, Avenzo Therapeutics, Inc. (“Avenzo”) and Fa…
Read attachment ↗d71655dex991.htm · S-4/A · 2026-10-14
Exhibit 99.1 CONSENT OF CITIZENS JMP SECURITIES, LLC We hereby consent to the use of our opinion letter, dated May 30, 2026, to the Board of Directors of Rallybio Corporation, included as Annex B to the proxy statement / prospectus which forms a part of the Registration Statement on Form S-4 of Rallybio Corporation, to be filed on the date hereof, and to the references to such opinion in such proxy statement / prospectus under the captions: “Prospectus Summary - Opinion of Citizens JMP Securit…
Read attachment ↗d71655dex991.htm · S-4/A · 2026-10-05
Exhibit 99.1 CONSENT OF CITIZENS JMP SECURITIES, LLC We hereby consent to the use of our opinion letter, dated May 30, 2026, to the Board of Directors of Rallybio Corporation, included as Annex B to the proxy statement / prospectus which forms a part of the Registration Statement on Form S-4 of Rallybio Corporation, to be filed on the date hereof, and to the references to such opinion in such proxy statement / prospectus under the captions: “Prospectus Summary - Opinion of Citizens JMP Securit…
Read attachment ↗d71655dex991.htm · S-4/A · 2026-09-16
Exhibit 99.1 CONSENT OF CITIZENS JMP SECURITIES, LLC We hereby consent to the use of our opinion letter, dated May 30, 2026, to the Board of Directors of Rallybio Corporation, included as Annex B to the proxy statement / prospectus which forms a part of the Registration Statement on Form S-4 of Rallybio Corporation, to be filed on the date hereof, and to the references to such opinion in such proxy statement / prospectus under the captions: “Prospectus Summary - Opinion of Citizens JMP Securit…
Read attachment ↗d71655dex991.htm · S-4/A · 2026-08-26
EX-99.1 5 d71655dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CONSENT OF CITIZENS JMP SECURITIES, LLC We hereby consent to the use of our opinion letter, dated May 30, 2026, to the Board of Directors of Rallybio Corporation, included as Annex B to the proxy statement / prospectus which forms a part of the Registration Statement on Form S-4 of Rallybio Corporation, to be filed on the date hereof, and to the references to such opinion in such proxy statement / prospectus under the captions: “Pros…
Read attachment ↗